Year: 2026
Type: article
Abstract: For the oral delivery of biologics, solid lipid nanoparticles (SLNs) have become a viable nanocarrier technology that addresses important issues such enzymatic degradation, low solubility, and restricted bioavailability of therapeutic proteins, peptides, and nucleic acids. While surface alterations enable targeted distribution to certain organs and enhanced absorption across biological barriers, their solid lipid matrix offers a protective environment that improves stability and permits regulated release. SLNs have the advantages of biocompatibility, biodegradability, and scalability over traditional carriers, which makes them appropriate for a variety of therapeutic uses. This thorough analysis examines recent preclinical and clinical data, assesses constraints including drug loading capacity and manufacturing difficulties, and highlights the design, formulation techniques, and mechanisms by which SLNs enhance oral administration of biologics. In order to offer SLNs as a flexible platform for upcoming oral biologic medicines, future prospects highlight their integration with cutting-edge biologics, such as monoclonal antibodies and RNA-based therapeutics.
Language: English
Subfield: Pharmaceutical Science
Domain: Life Sciences
Open Access status: bronze
OpenAlex ID: W7162688953